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In this original editorial piece, María Vallet-Regí, Patricia Mora-Raimundo, 
Daniel Lozano and Miguel Manzano (all at the Universidad Complutense de 
Madrid, Spain) discuss the use of nanoparticles for the potential treatment of 
osteoporosis, in light of some of their recently published work in the field. 
 
In the last few decades, the global life expectancy has risen considerably, which 
has consequently increased the impact of skeletal diseases, such as osteoporosis. 
In this sense, osteoporosis is defined by the WHO as a ‘progressive systemic 
skeletal disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue, with a consequent increase in bone fragility and 
susceptibility to fracture’ [1]. 
The bone remodeling process is governed by the action of osteoclasts, which 
resorb old bone, and osteoblasts, which subsequently stimulate new bone 
formation. Current conventional therapies are limited to two main groups: 
antiresorptive drugs, which slow down bone resorption and include 
bisphosphonates, denosumab, estrogen or raloxifene, among others, and anabolic 
drugs, which stimulate bone formation, such as teriparatide. Although these 
conventional drugs are effective in reducing the fracture risk and increasing bone 
mineral density , they present some limitations and side effects, which restrict their 
long-term administration and reduce treatment adherence. 
Recognition of signaling pathway targets has led to the development of new 
antiosteoporotic agents. As a consequence, new therapeutic approaches have 
been proposed for osteoporosis treatments, such as cathepsin K inhibitors, 
antisclerostin antibodies, parathyroid hormone  analogs or therapies based on gene 
expression modification by the application of small interfering RNAs (siRNAs) [2]. 
The main drawback of these therapies is their short half-lives due to degradation by 
different enzymes – proteases in the case of peptides and nucleases in the case of 
nucleic acids. Further, due to the complexity of diverse diseases such as 
osteoporosis, it has become increasingly clear that drugs administered alone, 
targeted to specific molecular pathways, present limitations. Therefore, another 
possible approach considered for increasing treatment efficacy is the combined use 
of several drugs, known as combination therapy. 
Over the last few years, nanoparticles have been found to be promising systems for 
efficient therapeutic delivery in bone disease therapy. The development of 
nanoparticles for bone regeneration in osteoporosis patients seems to be ideal, 
since bone itself is a nanocomposite. In addition to this dimensional similarity, 
nanoparticles can offer several benefits. First, they can enhance therapeutic 
delivery and increase tissue specificity, boosting therapy efficiency. They also 
provide drug protection from biodegradation and improve drug pharmacokinetics, 
pharmacodynamics, biodistribution and targeting, decreasing doses without 
sacrificing treatment efficacy [3]. Additionally, nanoparticles could also reduce 
exposure of the therapeutic agent to non-target cells, minimizing its potential side 
effects and improving the life quality of patients. Moreover, regarding combination 
therapy, nanoparticles could also play a key role in this field, offering the possibility 
of loading several drugs and transporting them to the target tissue. In this way, the 
number of medications required to be administered would be reduced and 
adherence could be potentially improved. 
In the frame of nanomedicine and, more specifically, in the field of osteoporosis 
treatment, different nanoparticles have been developed, such as liposomes, 
dendrimers, polymeric nanoparticles, iron oxide or gold nanoparticles, and 
mesoporous silica nanoparticles (MSNs), among others. Compared with other 
types of particles, MSNs present higher robustness due to their silica framework 
[4]. They are mechanically, thermally and chemically stable, allowing harsh reaction 
conditions for their modifications. MSNs have been used for the delivery of 
osteoporotic conventional drugs, such as alendronate, calcitonin or zoledronic acid, 
however, they could also be functionalized for the transport of nucleic acids, 
presenting a potential alternative method for delivering siRNAs to target cells. The 
mesoporous structure of the nanoparticles also allows the loading of several drugs 
and, therefore, empowers a dual treatment. 
In our recent work [5], which was  carried out in the context of the Advanced Grant 
VERDI (polyvalent mesoporous nanosystem for bone diseases) from the European 
Research Council (Brussels, Belgium), the purpose was to co-deliver two 
therapeutic agents – SOST siRNA and osteostatin – inside cells using MSNs as 
nanocarriers. The employed siRNA was selected to silence SOST, which is 
responsible for the expression of sclerostin, overexpression of which reduces 
osteoblast formation and differentiation through inhibition of the Wnt/β-catenin 
pathway. Thus, silencing SOST with a specific siRNA in osteocytes could represent 
an effective alternative treatment approach. Additionally, the network of cavities 
from MSNs allowed loading an osteogenic peptide, osteostatin – a parathyroid 
hormone–related peptide that has been observed to stimulate osteoblastic cell 
growth and differentiation. 
The developed platform was able to transport, co-deliver and 
transfect SOST siRNA and osteostatin, maintaining their activity and achieving an 
effective silencing effect. Surprisingly, the combination of SOST siRNA with the 
osteogenic peptide in ovariectomized mice resulted in a synergy – not only 
knocking down the selected gene, but also increasing the expression of early 
markers of osteogenic differentiation. This system has demonstrated remarkable 
efficacy for an intrabone marrow injection. In consequence, this system will 
constitute a potential candidate as a platform for gene therapy in osteoporosis 
treatment and might lead to further investigations. 
Taking everything stated above into consideration – and regarding the promising 
results obtained in our work – it could be concluded that nanoparticles and, more 
precisely, MSNs, present huge potential in the frame of osteoporosis treatment. 
However, there is still a huge amount of effort and research that needs to be done 
before translating this research into the clinic to improve patients’ conditions in the 
fight against osteoporosis. 
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